ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium

    Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma

    Suzanne Li1, Sarah Ishaq 2, Mary Buckley 3, Kathryn Torok 4, Barbara Edelheit 5, Kaleo Ede 6 and C. Egla Rabinovich 7, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Montclair State University, montclair, 3Duke University, Durham, 4Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, 5CT Children's Medical Center, Hartford, 6Phoenix Children's Hospital, Phoenix, 7Duke University Hospital, Durham

    Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
  • Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium

    Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile

    Sara Concha1, Pamela Morales 2, Eduardo Talesnik 1 and Arturo Borzutzky 1, 1Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, 2Department of Pediatric, Clinica Las Condes, Santiago, Chile

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
  • Abstract Number: 060 • 2020 Pediatric Rheumatology Symposium

    Parsing Apart the Pain Experience: Exploring Treatment-Related Pain in Juvenile Idiopathic Arthritis

    Yvonne Brandelli1, Christine Chambers 2, Perri Tutelman 1, Jennifer Stinson 3, Adam Huber 4 and Jennifer Wilson 5, 1Dalhousie University, Halifax, Nova Scotia, Canada, 2Dalhousie University & IWK Health Centre, Halifax, Nova Scotia, Canada, 3University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada, 4IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 5Cassie and Friends, Vancouver, British Columbia, Canada

    Background/Purpose: Pain is one of the most frequently reported symptoms among children with Juvenile Idiopathic Arthritis (JIA), and in recent decades our understanding and assessment…
  • Abstract Number: 065 • 2020 Pediatric Rheumatology Symposium

    Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis

    Jordan Jones1 and Michael Lypka 2, 1Children's Mercy Kansas City, Kansas City, 2Children's Mercy Kansas City, Kansas City, Missouri

    Background/Purpose: Temporomandibular joint (TMJ) arthritis is present in 40-96% of children with Juvenile Idiopathic Arthritis (JIA) (1). TMJ arthritis can be difficult to identify, treat,…
  • Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium

    Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis

    Rana Masoud1, Wajiha Jeelani 2, Barbine Agbor Agbor 3, Teresa Hennon 2, Brian Wrotniak 4 and Rabheh Abdul Aziz 2, 1Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, New York, 2Department of Pediatric Rheumatology, University at Buffalo, Oishei Children's Hospital, Buffalo, 3Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, 4Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, NY, USA, Buffalo

    Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…
  • Abstract Number: 080 • 2020 Pediatric Rheumatology Symposium

    Therapeutic Interferon Gamma Neutralization with Emapalumab in Patients with NRLC4- and CDC42-Associated Diseases Characterized by Recurrent and Severe Hemophagocytic Lymphohistiocytosis

    Claudia Bracaglia1, Antonella Insalaco 1, Giulia Marucci 1, Manuela Pardeo 1, Emanuela Sacco 1, Virginia Messia 1, Giusi Prencipe 1, Ivan Caiello 1, Sarka Fingerhutova 2, Pavla Dolezalova 2, Veronica Asnaghi 3, Maria Ballabio 3, Cristina de Min 3 and Fabrizio De Benedetti 1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, 3Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: Interferon gamma (IFNγ) is a pivotal mediator of HLH. Emapalumab (a fully human anti-IFNγ monoclonal antibody) is efficacious in patients with primary HLH. In…
  • Abstract Number: 093 • 2020 Pediatric Rheumatology Symposium

    Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

    Ginger Janow 1, Timothy Beukelman 2, Yukiko Kimura 3, Rayfel Schneider 4, Shalini Mohan 5, Gail Rodich 6 and Mary Beth Son7 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, New Jersey, 2University of Alabama at Birmingham, Birmingham, 3Hackensack Meridian School of Medicine, Hackensack, 4The Hospital for Sick Children, Toronto, Canada, 5Genentech, Inc., South San Francisco, 6Genentech, Mill Valley, 7Boston Children's Hospital, Boston, Massachusetts

    Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes.  There may…
  • Abstract Number: L11 • 2019 ACR/ARP Annual Meeting

    Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Thomas W.J. Huizinga 4, Gustavo Citera 5, Clifton Bingham 6, Subhashis Banerjee 7, Benjamin Soule 8, Marleen Nys 9, Sean Connolly 10, Robert Wong 10, Kuan-Hsiang Gary Huang 7 and Roy Fleischmann 11, 1University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, 4Leiden University Medical Center, Leiden, Netherlands, 5Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 6Johns Hopkins University, Baltimore, 7Bristol-Myers Squibb, Princeton, NJ, 8Bristol-Myers Squibb, Princeton, New Jersey, 9Bristol-Myers Squibb, Braine L'Alleud, Belgium, 10Bristol-Myers Squibb, Princeton, 11Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
  • Abstract Number: L13 • 2019 ACR/ARP Annual Meeting

    Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Philip J. Mease1, Proton Rahman 2, Alice B. Gottlieb 3, Elizabeth Hsia 4, Alexa Kollmeier 5, Xie Xu 6, Ramanand Subramanian 5, Prasheen Agarwal 5, Shihong Sheng 5, Bei Zhou 5, Désirée van der Heijde 7 and Iain McInnes 8, 1Swedish Medical Center and University of Washington, Seattle, Washington, 2Memorial University of Newfoundland, Newfoundland, Canada, 3Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, 5Janssen Research & Development, LLC, Spring House, Pennsylvania, 6Janssen Research & Development, LLC, Spring House, 7Leiden University Medical Center, Leiden, Netherlands, 8Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
  • Abstract Number: L17 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

    Eric Morand1, Richard Furie 2, Yoshiya Tanaka 3, Ian Bruce 4, Anca Askanase 5, Christophe Richez 6, Sang-Cheol Bae 7, Philip Brohawn 8, Lilia Pineda 9, Anna Berglind 10 and Raj Tummala 9, 1Monash University, Melbourne, Victoria, Australia, 2Zucker School of Medicine at Hofstra/Northwell, New York, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 5Columbia University, New York, 6CHU de Bordeaux-GH Pellegrin, Bordeaux, France, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Former employee of AstraZeneca, Gaithersburg, Maryland, 9AstraZeneca, Gaithersburg, Maryland, 10AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
  • Abstract Number: 522 • 2019 ACR/ARP Annual Meeting

    Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis

    Thierry Sornasse1, Jeremy Sokolove 1 and Iain McInnes 2, 1AbbVie Immunology Clinical Development, Redwood City, 2Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response (IR) to…
  • Abstract Number: 1329 • 2019 ACR/ARP Annual Meeting

    Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis

    Kevin Winthrop1, Mark Genovese 2, Bernard Combe 3, Yoshiya Tanaka 4, Alan Kivitz 5, Franziska Matzkies 6, Beatrix Bartok 6, Lei Ye 6, Ying Guo 6, Chantal Tasset 7, John Sundy 6, Edward Keystone 8, Rene Westhovens 9, William F.C. Rigby 10 and Gerd Burmester 11, 1Oregon Health and Science University, Portland, OR, 2Stanford University, Stanford, CA, 3CHU Montpellier, Montpellier University, Montpellier, France, 4University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 5Altoona Center for Clinical Research, Duncansville, PA, 6Gilead Sciences, Inc., Foster City, CA, 7Galapagos NV, Mechelen, Belgium, 8Mount Sinai Hospital and University of Toronto, Toronto, Canada, 9University Hospitals, Leuven, Belgium, 10Dartmouth College, Lebanon, NH, 11Charité—University Medicine Berlin, Berlin, Germany

    Background/Purpose: Filgotinib (FIL) is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) that is under development for the treatment of RA and other…
  • Abstract Number: 1557 • 2019 ACR/ARP Annual Meeting

    Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Daniela DiGuiseppe 2, Anne Gitte Loft 3, Manuel Pombo-Suarez 4, Herman Mann 5, Ziga Rotar 6, Florenzo Iannone 7, Tore Kvien 8, Maria José Santos 9, Kari K. Eklund 10, Bjorn Gudbjornsson 11, Catalin Codreanu 12, Sema Yılmaz 13, Johan Askling 14, Carlos Sánchez-Piedra 15, Karel Pavelka 5, Matija Tomsic 16, Fabrizio Conti 17, Joe Sexton 18, Helena Santos 19, Nina Trokovic 20, Thorvardur J Love 21, Ruxandra IONESCU 22, Yavuz Pehlivan 23, Michael J. Nissen 24, Gary Macfarlane 25, Irene van der Horst-Bruinsma 26, Stylianos Georgiadis 27, Lykke Midtbøll Ørnbjerg 28, Cecilie Heegaard Brahe 28, Merete Lund Hetland 29 and Mikkel Østergaard 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 4Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 5Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 6UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 7Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 8Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, 11Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 12Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 13Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, 14Karolinska Institutet, Stockholm, Sweden, 15Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 16Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 17Sapienza University of Rome, Rome, Italy, 18Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 19Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 20Helsinki University Central Hospital, Helsinki, Finland, 21Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 22SPITALUL CLINIC SFANTA MARIA, Bucharest, 23Uludağ University, Bursa, Turkey, 24University Hospital Geneva, Geneva, Switzerland, 25University of Aberdeen, Aberdeen, United Kingdom, 26Amsterdam University Medical Center, Amsterdam, Netherlands, 27DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 28Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 29DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 30Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a…
  • Abstract Number: 2559 • 2019 ACR/ARP Annual Meeting

    A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus

    W. Winn Chatham 1, Richard Furie 2, Amit Saxena 3, Philip Brohawn 4, Erik Schwetje5, Gabriel Abreu 6 and Raj Tummala 5, 1University of Alabama Medical Center, Birmingham, AL, 2Zucker School of Medicine at Hofstra/Northwell, New York, NY, 3NYU Langone Orthopedic Center, New York, 4AstraZeneca, Gaithersburg, MD, 5AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, 6AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: Anifrolumab is a fully human, IgG1κ monoclonal antibody that binds to the type I IFN receptor and inhibits activity of all type I IFNs.1…
  • Abstract Number: 524 • 2019 ACR/ARP Annual Meeting

    A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies

    Joel Kremer1, Filip Van den Bosch 2, Andrea Rubbert-Roth 3, Sebastiao Radominski 4, Gerd Burmester 5, Heidi Camp 6, Sebastian Meerwein 7, Mark Howard 8, Yanna Song 9, Sheng Zhong 10 and Bernard Combe 11, 1Albany Medical College, Albany, NY, 2Ghent University Hospital, Ghent, Belgium, 3Kantonsspital St. Gallen, St Gallen, Switzerland, 4Universidade Federal do Paraná, Curitiba, Brazil, 5Charité—University Medicine Berlin, Berlin, Germany, 6AbbVie Inc., North Chicago, IL, 7AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 8AbbVie Inc., North Chicago, 9AbbVie Inc., North Chicago, IL, USA, North Chicago, 10AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 11CHU Montpellier, Montpellier University, Montpellier, France

    Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has shown efficacy in patients with rheumatoid arthritis (RA) when combined with methotrexate (MTX) or other conventional synthetic…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology